Australia or New Zealand tech companies are in focus. We intend to target a business combination with a technology-oriented company in Australia and/or New Zealand. We are one of only a few SPACs primarily focused on acquisition targets in Australia and/or New Zealand. We believe that Australia and New Zealand have economic and social environments […]

Our CEO is Lei Huang, who is also the CEO of U.S. Tiger Securities.  We shall not undertake our initial business combination with any entity with its principal business operations or its headquarters in China (including Hong Kong and Macau). (Note: Fortune Rise Acquisition Corp. priced its SPAC IPO in sync with the terms in […]

CI&T is a provider of strategy, design and software engineering services to enable digital transformation for the world’s largest enterprises and fast-growing companies. As companies race to provide their end customers with a digital-first experience, our highly talented multidisciplinary teams of strategists, designers and engineers bring a 26-year track record of accelerating business innovations through […]

Expensify is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. Every day, people from all walks of life in organizations around the world use Expensify to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. Since our founding […]

We believe Nu is one of the world’s largest digital banking platforms (based on number of customers), and one of the leading technology companies in the world, with 48.1 million customers across Brazil, Mexico and Colombia as of Sept. 30, 2021. Our customers include about 28 percent of the population of Brazil aged 15 and above. […]

We are a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win technology platform. Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. We believe this represents a paradigm shift in the management of cancer and that our product candidates have the […]

We intend to focus our search on companies with operations in the vision sensing technologies (“VST”), including hardware chip solutions (such as chips, modules and systems), VST-related application software, artificial intelligence (“AI”) and other peripheral technologies that assist to integrate and/or supplement VST applications. There is no restriction in the geographic location of targets we […]

We intend to initially focus our search on identifying a prospective target business in the technology industries in the United States and other developed countries, with a special focus within the space technology, financial technology, technology, media and telecom (“TMT”) industries and related sectors. Though our sponsor is a Hong Kong company, a majority of our management […]

All of our products are prepared with proprietary ingredient systems that allow us to provide consumers with delicious meals that are designed to be high in protein, low in sugar, and made with gluten- and grain-free ingredients. Our base ingredient systems, which include (i) chicken and parmesan cheese, and (ii) plant-based proteins and fibers, are composed of […]

We are a molecular genetics cancer diagnostic company formed in 2021 to acquire PharmGenomics GmbH (“PharmGenomics“) with the purpose of commercializing their product portfolio in Europe and the United States. PharmGenomics has developed several IVD tests for the European market since it was founded in 2008. Our portfolio includes ColoAlert, a colorectal cancer (“CRC”) screening stool DNA […]